AiCuris Anti-infective Cures AG

General information
AiCuris Anti-infective Cures AG
Friedrich-Ebert-Str. 475
Building 302
42117 Wuppertal, North Rhine-Westphalia

Contact person: Holger Zimmermann, Chief Executive Officer
Company main phone: +49 (202) 317630
Company main fax:  +49 (202) 317631177
Year founded:2006
Source of foundation:Spin-off from company
Name of foundation source:Bayer Infection Research
No. of employees: At this location:  70
Corporate description / mission:
AiCuris is a pharmaceutical company focused on the discovery, research and development of antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.The company’s first product, Letermovir (Prevymis®) is a therapy for human cytomegalovirus (HCMV) infections.
State of ownership: Private / independent
Headquarters: Yes
  • Biotechnology - Therapeutics and Diagnostics
  • Anti-infectives
  • Proteins
  • Small molecules
Primary therapeutic areas:
  • Infectious and parasitic diseases / infectiology / parasitology
Business model:
  • In-licensing
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:2
Phase III:3
On the market:1
Description of products:
Prevymis® / Letermovir (AIC246)
Pritelivir (AIC316)
Artilysins®, etc.
Collaborations & Clients
Partnering strategy / collaborations:
Merck & Co.
Royalty Pharma
Hybridize Therapeutics